Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 11/20 | 0.81 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.63 |
| ▸ | FAAH | O00519 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.53 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14453635 | 1.00 | NOD1 (0.81) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL8293954 | 1.00 | NOD1 (0.81) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL9829501 | 1.00 | NOD1 (0.81) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL18560507 | 1.00 | NOD1 (0.81) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL8515462 | 1.00 | NOD1 (0.81) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL24787612 | 1.00 | NOD1 (0.81) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL9829505 | 1.00 | NOD1 (0.81) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL15649578 | 1.00 | NOD1 (0.81) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL22684646 | 1.00 | NOD1 (0.81) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL8293270 | 1.00 | NOD1 (0.81) | NOD1SLC6A5FAAHMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119473-A1 | ACYLATED OXYNTOMODULIN PEPTIDE ANALOG | DONG-A ST CO., LTD. (KR) | 2022-04-21 | — | — | US | disclosed |
| EP-2932981-B1 | Albumin-binding derivatives of GLP-1 | NOVO NORDISK AS (DK) | 2021-06-16 | — | — | EP | disclosed |
| CN-107624066-A | The cosmetic treatment method of hair | 莱雅公司 | 2018-01-23 | — | — | CN | disclosed |
| US-20160108102-A1 | Novel GLP-1 Derivatives | NOVO NORDISK AS (DK) | 2016-04-21 | — | — | US | disclosed |
| EP-2932981-A2 | Albumin-binding derivatives of GLP-1 | NOVO NORDISK A/S (DK) | 2015-10-21 | — | — | EP | disclosed |
| US-20130244931-A1 | Novel GLP-1 Derivatives | NOVO NORDISK AS (DK) | 2013-09-19 | — | — | US | disclosed |
| US-20130053315-A1 | NOVEL GLP-1 DERIVATIVES | NOVO NORDISK A/S | 2013-02-28 | — | — | US | disclosed |
| US-20130040884-A1 | ALBUMIN-BINDING CONJUGATES COMPRISING FATTY-ACID AND PEG | NOVO NORDISK A/S | 2013-02-14 | — | — | US | disclosed |
| US-20100305032-A1 | Novel GLP-1 Derivatives | NOVO NORDISK A/S (DK) | 2010-12-02 | — | — | US | disclosed |
| US-20100305032-A1 | Novel GLP-1 Derivatives | NOVO NORDISK A/S (DK) | 2010-12-02 | — | — | US | disclosed |
| US-20070203058-A1 | Novel Glp-1 Derivatives | NOVO NORDISK A/S (DK) | 2007-08-30 | — | — | US | disclosed |
| US-20070203058-A1 | Novel Glp-1 Derivatives | NOVO NORDISK A/S (DK) | 2007-08-30 | — | — | US | disclosed |
| WO-2005027978-A2 | ALBUMIN-BINDING DERIVATIVES OF THERAPEUTIC PEPTIDES | NOVO NORDISK A/S (DK) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040884-A1 | ALBUMIN-BINDING CONJUGATES COMPRISING FATTY-ACID AND PEG | FABP1, FABP2, FABP4 | NOD1 3894/4885SLC6A5 2901/4885FAAH 112/4885 |
| US-20130053315-A1 | NOVEL GLP-1 DERIVATIVES | GLP1R, GIPR, IAPP | NOD1 575/4885SLC6A5 2059/4885FAAH 1323/4885 |
| US-20160108102-A1 | Novel GLP-1 Derivatives | GLP1R, GIPR, IAPP | NOD1 575/4885SLC6A5 2059/4885FAAH 1323/4885 |
| US-20100305032-A1 | Novel GLP-1 Derivatives | GLP1R, GIPR, IAPP | NOD1 575/4885SLC6A5 2059/4885FAAH 1323/4885 |
| US-20070203058-A1 | Novel Glp-1 Derivatives | GLP1R, GIPR, NPY4R | NOD1 410/4885SLC6A5 2385/4885FAAH 3270/4885 |
| US-20220119473-A1 | ACYLATED OXYNTOMODULIN PEPTIDE ANALOG | GLP1R, GIPR, GPR119 | NOD1 386/4885SLC6A5 4071/4885FAAH 235/4885 |
| US-20130244931-A1 | Novel GLP-1 Derivatives | GLP1R, GIPR, IAPP | NOD1 575/4885SLC6A5 2059/4885FAAH 1323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.